drugset / Trial / NCT04161456
Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata
Phase 2
Completed
1 enrolled
Dr. Frank Behrens
Celgene Corporation · collabDermatology Department University Hospital Frankfurt · collab
NaSingle-groupOpen-labelTreatment
Summary
Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a clinical picture changes to a decrease of all signs of inflammation. Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option. In this study, treatment with Apremilast (Otezla®) will be performed in patients with acne conglobata to observe its preliminary efficacy and safety in an open label, single-centre proof of concept study design.
Timeline
- Start
- 2019-10-09
- Primary completion
- 2021-02-08
- Completion
- 2021-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apremilast | Small molecule | 30 mg | — |